Ann Oncol

1. ROUPRET M, Bertaut A, Pignot G, Neuzillet Y, et al
   ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
   Ann Oncol. 2025 Dec 31:S0923-7534(25)04787-8. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   
2. MEEKS JJ, Powles T
   Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer.
   Ann Oncol. 2025 Oct 17:S0923-7534(25)04962-2. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   

   
   Arch Esp Urol

3. BALLESTERO R, Alonso E, Garcia N, Garcia J, et al
   Impact of COVID-19 on Postoperative Complications in Minimal Invasive Radical Cystectomy: A Comprehensive Complication Index-Based Analysis.
   Arch Esp Urol. 2025;78:975-985.
   

   >> Share

   
   
4. KOSEOGLU H, Yalcin B, Eroglu T, Yucetas U, et al
   Qualitative Interferon-gamma Release Assay for Predicting Response to BCG Instillations in Bladder Cancer.
   Arch Esp Urol. 2025;78:1015-1021.
   

   >> Share

   
   
5. ZHONG X, Xiao M, Su F, Shi J, et al
   OTUB1 Promotes Stem-like Properties in Bladder Cancer by Stabilising SLC7A11 and Suppressing Ferroptosis through Deubiquitination.
   Arch Esp Urol. 2025;78:1072-1080.
   

   >> Share

   
   

   
   Arch Ital Urol Androl

6. BADHEEB AM, Alkhanbash O, Alzubaidi Q, Al Asmari A, et al
   Survival outcomes and prognostic factors in muscle-invasive bladder cancer: a retrospective cohort study from a Saudi Arabian tertiary center.
   Arch Ital Urol Androl. 2025 Oct 22:14119. doi: 10.4081/aiua.2025.14119.
   

   >> Share

   
   

   
   Biomed Res Int

7. RESEARCH INTERNATIONAL B
   RETRACTION: Downregulation of Long Noncoding RNA LUCAT1 Suppresses the Migration and Invasion of Bladder Cancer by Targeting miR-181c-5p.
   Biomed Res Int. 2025;2025:9842795.
   

   >> Share

   
   

   
   BJU Int

8. MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al
   Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
   BJU Int. 2025 Oct 22. doi: 10.1111/bju.70044.
   

   >> Share

   
   

   
   BMC Cancer

9. FANG C, Huang X, Dai J, He W, et al
   Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
   BMC Cancer. 2025;25:1613.
   

   >> Share

   
   

   
   BMC Public Health

10. LIU Z, Yu L, Yan F, Qi J, et al
    National and subnational trends of years of life lost and reduced life expectancy caused by bladder cancer in China from 2005 to 2020.
    BMC Public Health. 2025;25:3553.
    

    >> Share

    
    

    
    BMC Urol

11. ASSI A, Jalbout J, Youssef B, Diab E, et al
    BlaCancer: a mobile health solution for enhancing bladder cancer care.
    BMC Urol. 2025;25:262.
    

    >> Share

    
    
12. KARAKANLI MU, Kutluturk EG, Polat EC, Otunctemur A, et al
    Diagnostic value of serum DR-70 levels, a new fibrin-related biomarker, in bladder cancer patients.
    BMC Urol. 2025;25:264.
    

    >> Share

    
    

    
    Cancer Gene Ther

13. GUERRERO C, Casal M, Alierta C, Moreo E, et al
    NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.
    Cancer Gene Ther. 2025;32:1090-1097.
    

    >> Share

    
    

    
    Clin Drug Investig

14. KEAM SJ
    Mitomycin Intravesical Solution: First Approval.
    Clin Drug Investig. 2025;45:909-913.
    

    >> Share

    
    

    
    Ecotoxicol Environ Saf

15. ZHU G, Tan C, Li Y
    Multi-omics integrative analysis of the mechanisms linking environmental pollutant exposure to bladder cancer pathogenesis.
    Ecotoxicol Environ Saf. 2025;305:119251.
    

    >> Share

    
    

    
    Environ Res

16. KIM CH, Kim S, Kang YH, Kim S, et al
    Association between long-term exposure to a mixture of ambient air pollutants and the incidences of bladder and kidney cancers.
    Environ Res. 2025;285.
    

    >> Share

    
    

    
    Eur Radiol

17. BARENTSZ J, van Koeverden SW, van der Leest M
    VI-RADS is not enough: why image quality is the key to reliable bladder cancer staging.
    Eur Radiol. 2025 Oct 22. doi: 10.1007/s00330-025-12086.
    

    >> Share

    
    

    
    Eur Urol

18. JAZAYERI B, Wang X, Li R
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Oct 16:S0302-2838(25)04729-3. doi: 10.1016/j.eururo.2025.09.4168.
    

    >> Share

    
    
19. FU MZ, Ghodoussipour S, Packiam VT
    The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Oct 16:S0302-2838(25)04734-7. doi: 10.1016/j.eururo.2025.09.4173.
    

    >> Share

    
    

    
    Eur Urol Focus

20. WESTHOFEN T, Eismann L, Schulz GB, Bauer RM, et al
    Gender Disparities in Health-related Quality of Life Outcomes Following Radical Cystectomy for Bladder Cancer.
    Eur Urol Focus. 2025 Oct 16:S2405-4569(25)00257.
    

    >> Share

    
    

    
    Fr J Urol

21. MATHIEU R, Evanguelos X, Pierre Etienne G, Yves A, et al
    French recommendations of the AFU Oncology Committee FOR bladder Cancer: update 2025.
    Fr J Urol. 2025 Oct 17:103011. doi: 10.1016/j.fjurol.2025.103011.
    

    >> Share

    
    

    
    Front Oncol

22. SODERKVIST K, Haggstrom C, Hagberg O, Aljabery F, et al
    Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study.
    Front Oncol. 2025;15:1680916.
    

    >> Share

    
    
23. REN Q, Li Y, Chen H, Chen Y, et al
    Prognostic value of lymphocyte to monocyte ratio for the patients with bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2025;15:1601040.
    

    >> Share

    
    

    
    Front Public Health

24. MANDANACH C, Handra CM, Rascu A, Hohor S, et al
    Occupational hazards and bladder cancer-An umbrella review of the risk in workers exposed over the past 30 years.
    Front Public Health. 2025;13:1667873.
    

    >> Share

    
    

    
    Gene

25. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
    Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies" [Gene 970 (2025) 149772].
    Gene. 2025 Oct 21:149839. doi: 10.1016/j.gene.2025.149839.
    

    >> Share

    
    

    
    Imeta

26. ZHANG Z, Yuan C, Ge Q, Cao D, et al
    Bavachalcone targets transferrin receptor and sensitizes gemcitabine to affect bladder cancer progression.
    Imeta. 2025;4:e70071.
    

    >> Share

    
    

    
    Indian J Urol

27. MANDAL S
    Critical appraisal of a meta-analysis on pelvic lymph node dissection in muscle-invasive bladder cancer.
    Indian J Urol. 2025;41:321-322.
    

    >> Share

    
    

    
    Int J Cancer

28. TANG Y, Han Z, Yi X, Li J, et al
    Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder.
    Int J Cancer. 2025;157:2485-2494.
    

    >> Share

    
    

    
    Int Urol Nephrol

29. ZHANG T, Liu J, Feng L, Ke C, et al
    Prognostic prediction of incidental prostate cancer in radical cystoprostatectomy for muscle-invasive bladder cancer.
    Int Urol Nephrol. 2025 Oct 23. doi: 10.1007/s11255-025-04858.
    

    >> Share

    
    

    
    J Clin Oncol

30. BANDARI J, Messing EM
    Single-Arm Pivotal Studies in Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2025 Oct 21:JCO2501893. doi: 10.1200/JCO-25-01893.
    

    >> Share

    
    

    
    J Robot Surg

31. LI JM, Liu SM, Zhong MX, Wang L, et al
    Systematic review and meta-analysis of comparing open and robotic-assisted intracorporeal radical cystectomy: based on randomized controlled trials.
    J Robot Surg. 2025;19:700.
    

    >> Share

    
    

    
    Lancet

32. DE SANTIS M, Palou Redorta J, Nishiyama H, Krawczynski M, et al
    Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
    

    >> Share

    
    
33. NECCHI A, Briganti A, Montorsi F
    Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer.
    Lancet. 2025 Oct 17:S0140-6736(25)02015-X. doi: 10.1016/S0140-6736(25)02015.
    

    >> Share

    
    

    
    Med Lett Drugs Ther

34. 
    Intravesical gemcitabine (Inlexzo) for bladder cancer.
    Med Lett Drugs Ther. 2025;67:e176-e177.
    

    >> Share

    
    

    
    Minerva Urol Nephrol

35. FINATI M, Russo P, Pradere B
    Comment on: "Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer".
    Minerva Urol Nephrol. 2025;77:724-726.
    

    >> Share

    
    
36. PALUMBO S, Ferro M, Pandolfo SD, Romano L, et al
    Comment on: "The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach".
    Minerva Urol Nephrol. 2025;77:721-723.
    

    >> Share

    
    
37. TZELVES L, Day E, Bhudia A, Markov M, et al
    Organ-sparing robotic-assisted radical cystectomy in men: description of technique and outcomes.
    Minerva Urol Nephrol. 2025;77:700-707.
    

    >> Share

    
    
38. LASORSA F, Ditonno P, Lucarelli G
    Comment on: "The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper".
    Minerva Urol Nephrol. 2025;77:718-720.
    

    >> Share

    
    
39. PANDOLFO SD, Mir MC, Cerrato C, Russo P, et al
    From vintage to vanguard: has chemoablation's prime time finally arrived in bladder cancer treatment?
    Minerva Urol Nephrol. 2025;77:573-575.
    

    >> Share

    
    

    
    N Engl J Med

40. POWLES T, Kann AG, Castellano D, Gross-Goupil M, et al
    ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
    N Engl J Med. 2025 Oct 20. doi: 10.1056/NEJMoa2511885.
    

    >> Share

    
    

    
    Oncol Lett

41. GONG YQ, Peng D, Ning XH, Yang XY, et al
    Erratum: [Corrigendum] UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells.
    Oncol Lett. 2025;30:580.
    

    >> Share

    
    

    
    Urology

42. 
    Expression of Concern: "Letter to the Editor on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis"" [Urology, volume 199, 2025, 259-260].
    Urology. 2025;204:370.
    

    >> Share

    
    
43. REZAEE ME, Mahon KM, Su ZT, Luck KM, et al
    Characterizing Symptoms and Defining Toxicity in Ambulatory Transurethral Resection of Bladder Tumor: Results From a Multicenter Prospective Cohort Study.
    Urology. 2025;204:1-8.
    

    >> Share

    
    
44. LEE MS, Moschini M, Britton CJ, Longoni M, et al
    Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials.
    Urology. 2025;204:143-150.
    

    >> Share

    
    

    
    World J Urol

45. CINAR NB, Yilmaz H, Tasyurek EY, Kurt Pehlivanoglu M, et al
    Evaluation of inflammatory markers in survival analysis of patients undergoing radical cystectomy using machine learning.
    World J Urol. 2025;43:620.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share